Episode
2394: hVIVO Secures £6m Influenza Human Challenge Trial Contract
- Podcast
- The Vox Markets Podcast
- Published
- May 7, 2026
- Duration seconds
- 355
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8900463
Actions
POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2394-hvivo-secures-6m-influenza-human-challenge-trial-contract/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2394-hvivo-secures-6m-influenza-human-challenge-trial-contract.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Watch on YouTube Andrew Catchpole, Chief Scientific Officer of hVIVO joins Martin Luke of Vox Markets to discuss hVIVO’s newly signed £6 million influenza human challenge trial contract. Andrew explains how the study will evaluate a prophylactic antiviral treatment using hVIVO’s specialist influenza challenge model, highlighting the speed and efficiency advantages of human challenge trials, the growing focus on antiviral therapies, and why hVIVO continues to attract global clients.